Overall Survival in Cancer Drug Trials as a New Surrogate End Point for Overall Survival in the Real World
- 1 July 2017
- journal article
- viewpoint
- Published by American Medical Association (AMA) in JAMA Oncology
- Vol. 3 (7), 889-890
- https://doi.org/10.1001/jamaoncol.2016.5296
Abstract
This Viewpoint discusses overall survival in cancer trials as a surrogate end point for real-world patients.This publication has 5 references indexed in Scilit:
- An Appraisal of Clinically Meaningful Outcomes Guidelines for Oncology Clinical TrialsJAMA Oncology, 2016
- FDA subset analysis of the safety of nivolumab in elderly patients with advanced cancers.Journal of Clinical Oncology, 2016
- Sorafenib Effectiveness in Advanced Hepatocellular CarcinomaThe Oncologist, 2016
- Oral Anticancer Drugs: How Limited Dosing Options and Dose Reductions May Affect Outcomes in Comparative Trials and Efficacy in PatientsJournal of Clinical Oncology, 2014
- Under-Representation of Older Adults in Cancer Registration Trials: Known Problem, Little ProgressJournal of Clinical Oncology, 2012